{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:38:40Z","timestamp":1793252320797,"version":"4.5.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010731","name":"Faculty of Medicine, Chiang Mai University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jaip.2020.08.055","type":"journal-article","created":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T03:24:02Z","timestamp":1599535442000},"page":"956-970.e57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Comparative Efficacy and Acceptability of Licensed Dose Second-Generation Antihistamines in Chronic Spontaneous Urticaria: A Network Meta-Analysis"],"prefix":"10.1016","volume":"9","author":[{"given":"Phichayut","family":"Phinyo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pattaraporn","family":"Koompawichit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surapon","family":"Nochaiwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Napatra","family":"Tovanabutra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siri","family":"Chiewchanvit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mati","family":"Chuamanochan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2020.08.055_bib1","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA2LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.08.055_bib2","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jaip.2015.07.021","article-title":"Chronic idiopathic urticaria","volume":"3","author":"Wu","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.08.055_bib3","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40271-015-0145-9","article-title":"The impact of chronic urticaria from the patient\u2019s perspective: a survey in five European countries","volume":"8","author":"Balp","year":"2015","journal-title":"Patient"},{"key":"10.1016\/j.jaip.2020.08.055_bib4","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1111\/all.13209","article-title":"The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU","volume":"72","author":"Maurer","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.08.055_bib5","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.anai.2015.06.030","article-title":"Effect of chronic urticaria on US patients: analysis of the National Health and Wellness Survey","volume":"115","author":"Vietri","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.08.055_bib6","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/imr.12632","article-title":"The role and relevance of mast cells in urticaria","volume":"282","author":"Church","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaip.2020.08.055_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13223-019-0375-9","article-title":"CSACI position statement: newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria","volume":"15","author":"Fein","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2020.08.055_bib8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1398-9995.2009.02325.x","article-title":"Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper","volume":"65","author":"Church","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.08.055_bib9","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/jdv.14305","article-title":"Bilastine: a new H1-antihistamine with an optimal profile for updosing in urticaria","volume":"31","author":"Church","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2020.08.055_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.jaip.2020.08.055_bib11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11882-018-0789-3","article-title":"Chronic urticaria: comparisons of US, European, and Asian guidelines","volume":"18","author":"Shahzad Mustafa","year":"2018","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2020.08.055_bib12","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.jaci.2014.02.036","article-title":"The diagnosis and management of acute and chronic urticaria: 2014 update","volume":"133","author":"Bernstein","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.08.055_bib13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5415\/apallergy.2012.2.2.149","article-title":"Management of chronic urticaria in Asia: 2010 AADV consensus guidelines","volume":"2","author":"Chow","year":"2012","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.jaip.2020.08.055_bib14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/cea.12494","article-title":"BSACI guideline for the management of chronic urticaria and angioedema","volume":"45","author":"Powell","year":"2015","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2020.08.055_bib15","first-page":"190","article-title":"Clinical practice guideline for diagnosis and management of urticaria","volume":"34","author":"Kulthanan","year":"2016","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"Suppl 2","key":"10.1016\/j.jaip.2020.08.055_bib16","first-page":"S118","article-title":"[Mexican guidelines on the diagnosis and treatment of urticaria]","volume":"61","author":"Larenas-Linnemann","year":"2014","journal-title":"Rev Alerg Mex"},{"key":"10.1016\/j.jaip.2020.08.055_bib17","series-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 6.0. Updated July 2019","article-title":"Chapter 11: Undertaking network meta-analyses","author":"Chaimani","year":"2019"},{"key":"10.1016\/j.jaip.2020.08.055_bib18","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaip.2020.08.055_bib19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2165\/00003495-200059020-00020","article-title":"Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria","volume":"59","author":"Simpson","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.jaip.2020.08.055_bib20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jaip.2020.08.055_bib21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: an introduction for clinicians","volume":"12","author":"Rouse","year":"2017","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.jaip.2020.08.055_bib22","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.jaip.2020.08.055_bib23","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1398-9995.2008.01893.x","article-title":"Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients","volume":"64","author":"Potter","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.08.055_bib24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4103\/0972-6691.140783","article-title":"A\u00a0prospective study of comparison of efficacy and safety between levocetirizine and olopatadine in chronic idiopathic urticaria","volume":"28","author":"Mahawar","year":"2014","journal-title":"Indian J Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.08.055_bib25","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/ijd.12250","article-title":"Clinical effectiveness and safety of cetirizine versus rupatadine in chronic spontaneous urticaria: a randomized, double-blind, 6-week trial","volume":"53","author":"Dakhale","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2020.08.055_bib26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3889\/oamjms.2019.069","article-title":"The efficacy of a two-fold increase of H1-antihistamine in the treatment of chronic urticaria\u2014the Vietnamese experience","volume":"7","author":"Thi","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"key":"10.1016\/j.jaip.2020.08.055_bib27","series-title":"In: Methods Guide for Effectiveness and Comparative Effectiveness Reviews","article-title":"Handling continuous outcomes in quantitative synthesis","author":"Fu","year":"2008"},{"key":"10.1016\/j.jaip.2020.08.055_bib28","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(92)90054-Q","article-title":"Variance imputation for overviews of clinical trials with continuous response","volume":"45","author":"Follmann","year":"1992","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jaip.2020.08.055_bib29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2288-7-5","article-title":"Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data","volume":"7","author":"Friedrich","year":"2007","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jaip.2020.08.055_bib30","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2020.08.055_bib31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jaip.2020.08.055_bib32","series-title":"Statistical power analysis for the behavioral sciences.","author":"Cohen","year":"1988"},{"key":"10.1016\/j.jaip.2020.08.055_bib33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2020.08.055_bib34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jaip.2020.08.055_bib35","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.jaip.2020.08.055_bib36","doi-asserted-by":"crossref","first-page":"f2914","DOI":"10.1136\/bmj.f2914","article-title":"Demystifying trial networks and network meta-analysis","volume":"346","author":"Mills","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2020.08.055_bib37","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/eb-2017-102753","article-title":"Common pitfalls and mistakes in the set-up, analysis and interpretation of results in network meta-analysis: what clinicians should look for in a published article","volume":"20","author":"Chaimani","year":"2017","journal-title":"Evid Based Ment Health"},{"key":"10.1016\/j.jaip.2020.08.055_bib38","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ije\/dys222","article-title":"Evaluation of inconsistency in networks of interventions","volume":"42","author":"Veroniki","year":"2013","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jaip.2020.08.055_bib39","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2020.08.055_bib40","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jrsm.57","article-title":"Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions","volume":"3","author":"Chaimani","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jaip.2020.08.055_bib41","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A\u00a0GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2020.08.055_bib42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/0253-7613.62399","article-title":"Loratadine versus levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety","volume":"42","author":"Anuradha","year":"2010","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.jaip.2020.08.055_bib43","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1398-9995.1996.tb00092.x","article-title":"Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria","volume":"51","author":"Brostoff","year":"1996","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.08.055_bib44","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/0019-5154.159621","article-title":"Comparison of efficacy, safety and cost-effectiveness of rupatadine and olopatadine in patients of chronic spontaneous urticaria: a randomized, double-blind, comparative, parallel group trial","volume":"61","author":"Dakhale","year":"2016","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaip.2020.08.055_bib45","first-page":"223","article-title":"Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study","volume":"17","author":"Dubertret","year":"2007","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaip.2020.08.055_bib46","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0091-6749(99)70091-6","article-title":"A\u00a0double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria","volume":"104","author":"Finn","year":"1999","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.08.055_bib47","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1398-9995.2007.01330.x","article-title":"Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study","volume":"62","author":"Gimenez-Arnau","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.08.055_bib48","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4103\/0019-5154.37733","article-title":"Comparative efficacy of fexofenadine and levocetirizine in chronic idiopathic urticaria","volume":"52","author":"Godse","year":"2007","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaip.2020.08.055_bib49","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.alit.2016.08.004","article-title":"Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II\/III study","volume":"66","author":"Hide","year":"2017","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2020.08.055_bib50","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.alit.2018.06.002","article-title":"Efficacy and safety of rupatadine in Japanese adult and adolescent patients with chronic spontaneous urticaria: a double-blind, randomized, multicenter, placebo-controlled clinical trial","volume":"68","author":"Hide","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2020.08.055_bib51","first-page":"42","article-title":"A\u00a0comparative study of efficacy and safety of rupatadine versus desloratadine in patients with chronic idiopathic urticaria","volume":"3","author":"Kolasani","year":"2013","journal-title":"Asian J Biomed Pharm Sci"},{"key":"10.1016\/j.jaip.2020.08.055_bib52","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S1081-1206(10)61325-7","article-title":"Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study","volume":"94","author":"Kaplan","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.08.055_bib53","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-4632.2005.02609.x","article-title":"Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study","volume":"45","author":"Kapp","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2020.08.055_bib54","first-page":"1444","article-title":"Rupatadine and levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety","volume":"10","author":"Maiti","year":"2011","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.jaip.2020.08.055_bib55","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1081-1206(10)62515-X","article-title":"Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria","volume":"84","author":"Nelson","year":"2000","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.08.055_bib56","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00128071-200708010-00005","article-title":"Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial","volume":"8","author":"Ortonne","year":"2007","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2020.08.055_bib57","first-page":"649","article-title":"Emedastine difumarate versus loratadine in chronic idiopathic urticaria: a randomized, double-blind, controlled European multicentre clinical trial","volume":"16","author":"Pons-Guiraud","year":"2006","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaip.2020.08.055_bib58","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3109\/09546634.2012.750414","article-title":"Olopatadine versus levocetirizine in chronic urticaria: an observer-blind, randomized, controlled trial of effectiveness and safety","volume":"24","author":"Sil","year":"2013","journal-title":"J\u00a0Dermatol Treat"},{"key":"10.1016\/j.jaip.2020.08.055_bib59","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1398-9995.2009.02217.x","article-title":"Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study","volume":"65","author":"Zuberbier","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.08.055_bib60","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/j.1365-2222.2012.03957.x","article-title":"H(1)-antihistamines and urticaria: how can we predict the best drug for our patient?","volume":"42","author":"Church","year":"2012","journal-title":"Clin Exp Allergy"},{"issue":"Suppl 2","key":"10.1016\/j.jaip.2020.08.055_bib61","first-page":"41","article-title":"Antihistamines in the treatment of chronic urticaria","volume":"17","author":"J\u00e1uregui","year":"2007","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2020.08.055_bib62","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1365-2222.2007.02662.x","article-title":"Inhibition of the histamine-induced weal and flare response: a valid surrogate measure for antihistamine clinical efficacy?","volume":"37","author":"Devillier","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2020.08.055_bib63","doi-asserted-by":"crossref","first-page":"S798","DOI":"10.1016\/S0091-6749(97)70128-3","article-title":"Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines","volume":"99","author":"Monroe","year":"1997","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.08.055_bib64","doi-asserted-by":"crossref","first-page":"177","DOI":"10.18176\/jiaci.0039","article-title":"Prediction of the efficacy of antihistamines in chronic spontaneous urticaria based on initial suppression of the histamine-induced wheal","volume":"26","author":"S\u00e1nchez","year":"2016","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2020.08.055_bib65","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1034\/j.1398-9995.1999.00032.x","article-title":"A\u00a0double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects","volume":"54","author":"Grant","year":"1999","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.08.055_bib66","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1081-1206(10)62483-0","article-title":"Twenty-four hours of activity of cetirizine and fexofenadine in the skin","volume":"86","author":"Purohit","year":"2001","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.08.055_bib67","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1034\/j.1398-9995.2001.00726.x","article-title":"A\u00a0randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine-induced cutaneous responses in healthy adult volunteers","volume":"56","author":"Devalia","year":"2001","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.08.055_bib68","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1081-1206(10)61995-3","article-title":"A\u00a0double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects","volume":"88","author":"Grant","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.08.055_bib69","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s00011-003-1193-5","article-title":"Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin","volume":"52","author":"Denham","year":"2003","journal-title":"Inflamm Res"},{"issue":"Suppl 1","key":"10.1016\/j.jaip.2020.08.055_bib70","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1007\/s000110300050","article-title":"H1 antagonists: receptor affinity versus selectivity","volume":"52","author":"Gillard","year":"2003","journal-title":"Inflamm Res"},{"key":"10.1016\/j.jaip.2020.08.055_bib71","first-page":"551","article-title":"Comparative efficacy of wheal-and-flare suppression among various non-sedating antihistamines and the pharmacologic insights to their efficacy","volume":"87","author":"Roongapinun","year":"2004","journal-title":"J\u00a0Med Assoc Thail Chotmaihet Thangphaet"},{"key":"10.1016\/j.jaip.2020.08.055_bib72","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S1081-1206(10)61264-1","article-title":"Similar rapid onset of action and magnitude of effect of fexofenadine and cetirizine as assessed by inhibition of histamine-induced wheal-and-flare reaction","volume":"93","author":"Purohit","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.08.055_bib73","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1472-8206.2004.00254.x","article-title":"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans","volume":"18","author":"Molimard","year":"2004","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.jaip.2020.08.055_bib74","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S1081-1206(10)61429-9","article-title":"Comparative activity of cetirizine and desloratadine on histamine-induced wheal-and-flare responses during 24 hours","volume":"92","author":"Purohit","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.08.055_bib75","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00011-005-1368-3","article-title":"Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines","volume":"54","author":"Gillard","year":"2005","journal-title":"Inflamm Res"},{"key":"10.1016\/j.jaip.2020.08.055_bib76","first-page":"449","article-title":"[The effect of 5-days of cetirizine, desloratadine, fexofenadine 120 and 180 mg, levocetirizine, loratadine treatment on the histamine-induced skin reaction and skin blood flow\u2014a randomized, double-blind, placebo controlled trial]","volume":"21","author":"K\u0142os","year":"2006","journal-title":"Pol Merkur Lek Organ Pol Tow Lek"},{"key":"10.1016\/j.jaip.2020.08.055_bib77","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00011-011-0373-y","article-title":"Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans","volume":"60","author":"Church","year":"2011","journal-title":"Inflamm Res"},{"key":"10.1016\/j.jaip.2020.08.055_bib78","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2340\/00015555-1490","article-title":"The inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy Caucasian and Japanese volunteers","volume":"93","author":"Schoepke","year":"2013","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2020.08.055_bib79","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/1346-8138.12326","article-title":"Evaluation of the antihistamine effects of olopatadine and levocetirizine during a 24-h period: a double-blind, randomized, cross-over, placebo-controlled comparison in skin responses induced by histamine iontophoresis","volume":"40","author":"Takeo","year":"2013","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2020.08.055_bib80","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/03007995.2016.1240665","article-title":"Comparative efficacy of bilastine, desloratadine and rupatadine in the suppression of wheal and flare response induced by intradermal histamine in healthy volunteers","volume":"33","author":"Antonijoan","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaip.2020.08.055_bib81","doi-asserted-by":"crossref","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2020.08.055_bib82","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/icvts\/ivy163","article-title":"Statistical primer: heterogeneity, random- or fixed-effects model analyses?","volume":"27","author":"Barili","year":"2018","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.jaip.2020.08.055_bib83","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2340\/00015555-2941","article-title":"Clinical features of chronic spontaneous urticaria that predict disease prognosis and refractoriness to standard treatment","volume":"98","author":"Curto-Barredo","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2020.08.055_bib84","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13601-019-0275-6","article-title":"Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study","volume":"9","author":"Ulambayar","year":"2019","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2020.08.055_bib85","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1398-9995.2008.01726.x","article-title":"How to assess disease activity in patients with chronic urticaria?","volume":"63","author":"M\u0142ynek","year":"2008","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.08.055_bib86","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/all.13271","article-title":"Comparison and interpretability of the available urticaria activity scores","volume":"73","author":"Hawro","year":"2018","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.08.055_bib87","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1002\/sim.8383","article-title":"Identifying inconsistency in network meta-analysis: is the net heat plot a reliable method?","volume":"38","author":"Freeman","year":"2019","journal-title":"Stat Med"},{"key":"10.1016\/j.jaip.2020.08.055_bib88","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1086\/209469","article-title":"Effect-size estimates: issues and problems in interpretation","volume":"23","author":"Fern","year":"1996","journal-title":"J\u00a0Consum Res"},{"key":"10.1016\/j.jaip.2020.08.055_bib89","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/ije\/dys124","article-title":"Methods to convert continuous outcomes into odds ratios of treatment response and numbers needed to treat: meta-epidemiological study","volume":"41","author":"da Costa","year":"2012","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jaip.2020.08.055_bib90","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","article-title":"GRADE guidelines: 13. Preparing Summary of Findings tables and evidence profiles\u2014continuous outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jaip.2020.08.055_bib91","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2288-14-30","article-title":"Which is more generalizable, powerful and interpretable in meta-analyses, mean difference or standardized mean difference?","volume":"14","author":"Takeshima","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jaip.2020.08.055_bib92","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","article-title":"Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report","volume":"66","author":"Maurer","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.08.055_bib93","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/0253-7613.62399","article-title":"Loratadine versus levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety","volume":"42","author":"Anuradha","year":"2010","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.jaip.2020.08.055_bib94","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1398-9995.1996.tb00092.x","article-title":"Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria","volume":"51","author":"Brostoff","year":"1996","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.08.055_bib95","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/ijd.12250","article-title":"Clinical effectiveness and safety of cetirizine versus rupatadine in chronic spontaneous urticaria: a randomized, double-blind, 6-week trial","volume":"53","author":"Dakhale","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2020.08.055_bib96","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/0019-5154.159621","article-title":"Comparison of efficacy, safety and cost-effectiveness of rupatadine and olopatadine in patients of chronic spontaneous urticaria: a randomized, double-blind, comparative, parallel group trial","volume":"61","author":"Dakhale","year":"2016","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaip.2020.08.055_bib97","first-page":"223","article-title":"Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study","volume":"17","author":"Dubertret","year":"2007","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaip.2020.08.055_bib98","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0091-6749(99)70091-6","article-title":"A\u00a0double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria","volume":"104","author":"Finn","year":"1999","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.08.055_bib99","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1398-9995.2007.01330.x","article-title":"Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study","volume":"62","author":"Gimenez-Arnau","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.08.055_bib100","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4103\/0019-5154.37733","article-title":"Comparative efficacy of fexofenadine and levocetirizine in chronic idiopathic urticaria","volume":"52","author":"Godse","year":"2007","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaip.2020.08.055_bib101","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.alit.2016.08.004","article-title":"Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II\/III study","volume":"66","author":"Hide","year":"2017","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2020.08.055_bib102","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.alit.2018.06.002","article-title":"Efficacy and safety of rupatadine in Japanese adult and adolescent patients with chronic spontaneous urticaria: a double-blind, randomized, multicenter, placebo-controlled clinical trial","volume":"68","author":"Hide","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2020.08.055_bib103","first-page":"42","article-title":"A\u00a0comparative study of efficacy and safety of rupatadine versus desloratadine in patients with chronic idiopathic urticaria","volume":"3","author":"Kolasani","year":"2013","journal-title":"Asian J Biomed Pharm Sci"},{"key":"10.1016\/j.jaip.2020.08.055_bib104","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S1081-1206(10)61325-7","article-title":"Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study","volume":"94","author":"Kaplan","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.08.055_bib105","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-4632.2005.02609.x","article-title":"Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study","volume":"45","author":"Kapp","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2020.08.055_bib106","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4103\/0972-6691.140783","article-title":"A\u00a0prospective study of comparison of efficacy and safety between levocetirizine and olopatadine in chronic idiopathic urticaria","volume":"28","author":"Mahawar","year":"2014","journal-title":"Indian J Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.08.055_bib107","first-page":"1444","article-title":"Rupatadine and levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety","volume":"10","author":"Maiti","year":"2011","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.jaip.2020.08.055_bib108","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1081-1206(10)62515-X","article-title":"Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria","volume":"84","author":"Nelson","year":"2000","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.08.055_bib109","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00128071-200708010-00005","article-title":"Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial","volume":"8","author":"Ortonne","year":"2007","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2020.08.055_bib110","first-page":"649","article-title":"Emedastine difumarate versus loratadine in chronic idiopathic urticaria: a randomized, double-blind, controlled European multicentre clinical trial","volume":"16","author":"Pons-Guiraud","year":"2006","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaip.2020.08.055_bib111","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1398-9995.2008.01893.x","article-title":"Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients","volume":"64","author":"Potter","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.08.055_bib112","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3109\/09546634.2012.750414","article-title":"Olopatadine versus levocetirizine in chronic urticaria: an observer-blind, randomized, controlled trial of effectiveness and safety","volume":"24","author":"Sil","year":"2013","journal-title":"J\u00a0Dermatol Treat"},{"key":"10.1016\/j.jaip.2020.08.055_bib113","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3889\/oamjms.2019.069","article-title":"The efficacy of a two-fold increase of H1-antihistamine in the treatment of chronic urticaria\u2014the Vietnamese experience","volume":"7","author":"Thi","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"key":"10.1016\/j.jaip.2020.08.055_bib114","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1398-9995.2009.02217.x","article-title":"Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study","volume":"65","author":"Zuberbier","year":"2010","journal-title":"Allergy"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219820309405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219820309405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:28:59Z","timestamp":1761974939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219820309405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":114,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S2213219820309405"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2020.08.055","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Efficacy and Acceptability of Licensed Dose Second-Generation Antihistamines in Chronic Spontaneous Urticaria: A Network Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2020.08.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}